Publicacions en col·laboració amb investigadors/es de Peking Union Medical College Hospital (2)

2019

  1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

1999

  1. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

    Osteoporosis International, Vol. 9, Núm. 5, pp. 461-468